Citadel Advisors’s SAB Biotherapeutics SABS Stock Holding History

Citadel Advisors’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$102K	Buy	+26,700	New	+$106K	﹤0.01%	12003

Other funds holding SABS

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's SABS Position: Q1 2026 in Review

Citadel Advisors sold out of SAB Biotherapeutics (SABS) in Q1 2026, closing a stake of 17,650 shares — an estimated $70.4K sold.

Citadel Advisors first reported a position in SABS in Q1 2021 and held it in 11 quarters. The position peaked at $452K in Q1 2021. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

Citadel Advisors reported no remaining SAB Biotherapeutics position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 17,650 SAB Biotherapeutics shares in Q1 2026, an estimated $70.4K.
Citadel Advisors first reported a position in SAB Biotherapeutics in Q1 2021 and held it in 11 quarters.
Citadel Advisors's SAB Biotherapeutics position peaked at $452K in Q1 2021.
76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.